Introduction
gastroesophageal junction cancer
DISEASE, GASTROESOPHAGEAL JUNCTION CANCER, DISEASE PROGRESSION
Patients with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) generally have a poor prognosis (Hsu et al. Disease progression is common after first- and second-line treatments in patients with mGC/GEJC, necessitating viable third-line treatment options for these patients (Chrom et al. The TAGS population had received ≥ 2 standard-of-care regimens for advanced disease, and there was no upper limit on the number of prior therapies a patient could have received; in addition, the prior therapy sequence was not specified (Shitara et al. In this analysis, we examined whether prior treatment with RAM, RAM plus paclitaxel (PAC), or IRI, standard second-line treatments for mGC/GEJC, influenced efficacy or safety outcomes in the phase III TAGS trial.